Home » Newsletters » BioWorld Science

BioWorld Science

April 6, 2017

View Archived Issues

Lakewood-Amedex advancing second bisphosphocin candidate

Sentien Biotechnologies closes series A financing to fund development of SBI-101

FDA grants orphan drug designation to valproic acid for DLBCL

ProMetic Life Sciences completes plasminogen BLA filing

ConverGene enters CRADA with NINDS

Promising preclinical data for novel first-in-class pan-FGFR antibody, MM-161

Finch Therapeutics, Takeda to jointly develop FIN-524 for IBD

Pivotal ZEUS trial of Zolyd in cUTI meets primary endpoint

Allergan reports data from proof-of-concept phase II trial of Botox in major depressive disorder

Ligand and Marinus enter new agreement for Captisol-enabled ganaxolone

Charles River Laboratories and Nimbus Therapeutics enter strategic partnership

FUJIFILM presents novel irreversible and potent FLT3 inhibitor for AML treatment

Battelle and Nanotherapeutics form alliance on medical countermeasures

Enumeral Biomedical enters MoU with ICAV to pursue infectious disease collaboration

Takeda enrolls more than 20,000 children and adolescents in phase III dengue vaccine trial

R-IMPP, a new small molecule anti-secretagogue of PCSK9 with a new mechanism of action

Galapagos doses first patient in EQUATOR study of filgotinib

Corbus Pharmaceuticals to begin phase III study of anabasum in systemic sclerosis

First-in-human results for GSK-2881078 in the treatment of muscle wasting

Marina Biotech provides corporate update

Suven Life Sciences presents muscarinic acetylcholine M1 receptor PAMs

Calitor Sciences patents JAK, FLT3 and ARK kinase inhibitors

Merck KGaA divulges IRAK inhibitors

Ohio State University and collaborator identify estrogen receptor beta agonists

Metacrine discovers farnesoid X-activated receptor agonists

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 23, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.